Researchers offer hope for an oral, noninjectable treatment of acromegaly
31 March 2020

Acromegaly is a rare condition resulting from too much growth hormone, which causes large hands and feet, altered facial features and often heavy sweating, according to the Hormone Health Network. It also can lead to high blood pressure and diabetes. Usually a noncancerous tumor in the pituitary gland causes acromegaly.

If surgical removal of the pituitary tumor does not cure the condition, one of the current treatments consists of monthly injections of a drug called a somatostatin analog, said OPTIMAL study principal investigator Susan Samson, M.D., Ph.D., medical director, Pituitary Center, Baylor St. Luke's Medical Center in Houston, Texas. She said these injections can be effective but have limitations, including suboptimal symptom control in some patients, pain at the injection site and lost workdays.

"The results of this study suggest that if oral octreotide capsules are approved by the Food and Drug Administration, this drug has the potential to expand the treatment options for adults with acromegaly beyond injectables," Samson said.

The drug manufacturer, Chiasma in Needham, Mass., reported that the FDA is considering its resubmitted new drug application for octreotide capsules, whose brand name would be MYCAPSSA. If accepted, octreotide capsules would become the first oral somatostatin analog for treatment of acromegaly in adults, according to Chiasma, which funded the OPTIMAL (Octreotide capsules vs. Placebo Treatment In MultinationAL centers) study.

Fifty-six adults with active acromegaly participated in the nine-month study, with 28 patients each randomly assigned to receive either octreotide capsules or placebo (inactive) capsules. Neither the patients nor the investigators knew which treatment they were receiving, and all patients stopped their injections one month before the study.

Excess growth hormone raises levels of IGF-1, a hormone that reflects growth hormone activity better than measuring growth hormone, Samson said. Therefore, the study defined successful maintenance of a response to octreotide capsules as blood values of insulin-like growth factor-1 (IGF-1) being within the upper limit of normal when averaged at 34 and 36 weeks of treatment. Average IGF-1 levels in patients receiving octreotide capsules were in the normal range at the end of treatment but exceeded normal limits in patients receiving placebo, Samson reported.

"Octreotide capsules appeared safe and well
tolerated," she said, adding that 90 percent of patients completing oral octreotide therapy chose to continue treatment in a long-term extension study.

Provided by The Endocrine Society

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.